Laurus Labs Q1 net profit soars 126% to ₹368 crore
AI Summary
Laurus Labs reported a remarkable 126% increase in net profit to ₹368 crore for Q1 2026, alongside a 29% rise in total revenue to ₹2026 crore. The company attributes this growth to enhanced commercial deliveries and a strong performance in its Affordable Medicines portfolio, while also investing significantly in R&D to bolster its Advanced Biologics infrastructure.
Laurus Labs net profit increased 126 percent at ₹368 crore in the first quarter ended June 30, 2026 compared to ₹163 crore in the corresponding quarter of previous financial year.
The total revenue of the Hyderabad-based company increased 29 percent at ₹2026 crore against ₹1570 crore in the year-ago period.
“Laurus has delivered record quarterly revenue with expanded profitability and continued its portfolio transformation. This was driven by growing commercial deliveries within CDMO and continued strength in the Affordable Medicines portfolio,’’ Satyanarayana Chava, Founder & Chief Executive Officer said in a release on Friday.
During the quarter, the company strengthened its Integrated offerings, niche capabilities and also achieved important milestones, including agreement to in-license two Antibody Drug Conjugates (ADCs) and securing final handover of new land parcel, he added.
The total R&D investments including capex R&D for the quarter was ₹ 118 crore which increased by 74 percent year on year due to development efforts toward building Advanced Biologics infrastructure (Gene Therapy/Antibody Drug Conjugates
Laurus Labs had in-licensed two ADC assets from Aarvik Therapeutics for development and commercialization for India markets.
Original Article
Published on Hindu BusinessLine